Covid 19: A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination with Ad26

Grants and Contracts Details

StatusActive
Effective start/end date7/26/216/28/23

Funding

  • Janssen Vaccines and Prevention BV: $1,044,347.00